XLRN Acceleron Pharma Inc.

+0.17  (0%)
Previous Close 39.03
Open 39.06
Price To book 9.16
Market Cap 1728346777
Shares 44,090,479
Volume 193,303
Short Ratio 4.55
Av. Daily Volume 470,315

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 1H 2018.
Pulmonary arterial hypertension (PAH)
Phase 3 trial to be initiated early 2018.
Luspatercept - COMMANDS
First-line, lower-risk Myelodysplastic syndromes (MDS)
Phase 2 trial is underway - noted September 19, 2017.
Phase 3 trial to be initiated in 2018.
Luspatercept - COMMANDS
Myelodysplastic syndromes (MDS) cancer - first-line
Phase 2 commencement of dosing announced August 1, 2017.
Charcot-Marie-Tooth disease (CMT)
Phase 2 updated data at ASH 2016.
Low or intermediate-risk MDS patients who are erythropoiesis-stimulating agent (ESA) naïve or ring sideroblast negative (RS-)
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
Luspatercept - BELIEVE
b -thalassemia
Phase 2 dosing initiation announced December 22, 2016. Initial data due late 2017.
Facioscapulohumeral muscular dystrophy
Phase 2 data released June 12, 2017 - primary endpoint not met.
Dalantercept - DART Study
Renal Cell Carcinoma (RCC) - cancer

Latest News

  1. Options Traders Expect Huge Moves in Acceleron Pharma (XLRN) Stock
  2. 4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate
  3. Acceleron Announces Closing of Underwriters’ Option to Purchase Additional Shares
  4. Today's Research Reports on Stocks to Watch: Celgene Corporation and Acceleron Pharma
  5. [$$] Celgene Invests in Acceleron, BeiGene
  6. Stocks Flashing Renewed Technical Strength: Acceleron Pharma
  7. Acceleron Pharma Reaches 80-Plus Relative Strength Rating Benchmark
  8. Acceleron Pharma Trying To Close In On Key Technical Measure
  9. Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : September 25, 2017
  10. What Is Acceleron Pharma Inc’s (XLRN) Share Price Doing?
  11. Acceleron Announces Pricing of Public Offering of Common Stock
  12. Acceleron Announces Proposed Public Offering of Common Stock
  13. Acceleron Showcases Vision and Strategy at 2017 R&D Day
  14. Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension
  15. Acceleron to Host Research and Development Day on September 19, 2017
  16. ETFs with exposure to Acceleron Pharma, Inc. : September 7, 2017
  17. Acceleron Pharma, Inc. :XLRN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
  18. Acceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet Oncology
  19. Stocks To Watch: Acceleron Pharma Sees Relative Strength Rating Jump To 93
  20. Edited Transcript of XLRN earnings conference call or presentation 3-Aug-17 9:00pm GMT